



# PRESS RELEASE

## **Indoco enters into a strategic distribution partnership with Clarity Pharma, UK**

**Mumbai, December 2, 2024:** Indoco Remedies Limited (“**Indoco**”), a fully integrated, research based pharma company with a strong global presence announced today of a strategic collaboration between Indoco Remedies and **Clarity Pharma, UK**. This partnership marks a significant milestone in Indoco’s history, as the company will launch around 20 products over the next 18 months through Clarity Pharma, its distributor in the UK. The Company will continue to supply all the products under existing B2B partnership to its clients.

**Ms. Aditi Panandikar, Managing Director, Indoco Remedies Ltd.**, commented, “This collaboration with Clarity Pharma is a significant milestone for Indoco as this will further strengthen our foothold in the UK pharma market. By combining Indoco’s robust portfolio of high-quality, affordable pharmaceutical products with Clarity Pharma’s strong distribution network and market expertise, we are poised to deliver innovative healthcare solutions to a broader patient base.”

Mr. Steve Soper, CEO of Clarity Pharma commented, ‘Today is the beginning of a truly exciting journey between Indoco and Clarity and is the result of several years’ hard work in putting this market access project together. The range of Indoco products is exciting and extensive and will deliver significant savings to the market once launched, we look forward to a bright future of collaboration, growth, and making a difference in the affordability of a wide range of medicines’.

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company’s turnover is US\$ 212 million with a human capital of over 6000 employees, including over 400 skilled scientists and field staff who are the strength of the organization.

Clarity Pharma has over 25 years of experience in bringing products to market and now services over 4,000 Primary Healthcare customers.

**About Indoco Remedies Limited:**

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company's turnover is US\$ 212 million with a human capital of over 6000 employees, including over 400 skilled scientists and field staff who are the strength of the organization.

The Company has 11 manufacturing facilities, 7 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 106 million prescriptions annually from over 2,35,000 doctors belonging to various specialties. Indoco has 8 domestic marketing divisions a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynaecology etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensiform, Sensodent-KF, Aloja, Glychek, Kidodent, Subitral, Rexidin, MCBM 69, Methycal, Dropizine, Noxa, Homide, Cal-Aid, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit [www.indoco.com](http://www.indoco.com)

**For Media Inquiries Please Contact:**

**Corporate Communications** | Mobile: +91 22 62871000

E-mail: [corpcom@indoco.com](mailto:corpcom@indoco.com)